Early trials of a drug- Dostarlimab to treat rectal cancer led to remission in every participant. Colorectal cancer diagnoses are increasing in young adults, despite decreases in older adults. Providing nonsurgical treatment options is essential for better quality of life after cancer. This was the first time; an immunotherapy drug has generated a 100% remission rate for a specific form of rectal cancer.
This promising study of 12 patients, which was led by Memorial Sloan Kettering Cancer Center (MSKCC), made headlines around the world on June 6, 2022.
Dr. Ankita Dave
Ph.D. graduate from CSIR-Central Salt & Marine Chemical Research Institute
About the author: My subject of interest is Molecular Biology. I am passionate about research and want to gain more experience in this field. However, writing has always been my way of expressing and Science communication is something that includes both my interests, and I am intrigued to learn more
about this field.
